Please Wait
Applying Filters...
menu
    • menu
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Evenamide

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Newron Boosts Evenamide IP With EU Patent On 'Crystalline Forms'
    Newron Boosts Evenamide IP With EU Patent On 'Crystalline Forms'

    06 Jan 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-01-06/newron-further-expands-intellectual-property-portfolio-for-evenamide-with-new-eu-composition-of-matter-patent-ep4615820-crystalline-forms-of-even

    PHARMIWEB
    06 Jan 2026
    Share Share
    Newron Launches ENIGMA-TRS 2 Phase III Study In US For Evenamide
    Newron Launches ENIGMA-TRS 2 Phase III Study In US For Evenamide

    08 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251208306491/en/Newron-Announces-the-US-Initiation-of-Its-ENIGMA-TRS-2-Phase-III-Global-Clinical-Study-With-Evenamide-as-an-Add-On-Therapy-for-Patients-With-Treatment-Resistant-Schizophrenia-TRS

    BUSINESSWIRE
    08 Dec 2025
    Share Share
    Newron To Present Evenamide Schizophrenia Data At (ECNP) Congress
    Newron To Present Evenamide Schizophrenia Data At (ECNP) Congress

    02 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251002836097/en/Newron-to-Present-New-Analyses-From-and-Updates-on-its-Clinical-Program-Evaluating-Evenamide-as-an-Add-on-Treatment-for-Schizophrenia-at-the-38th-European-College-of-Neuropsychopharmacology-ECNP-Congress-2025

    BUSINESSWIRE
    02 Oct 2025
    Share Share
    Newron to Present Evenamide Data for Schizophrenia at 2025 WCBP
    Newron to Present Evenamide Data for Schizophrenia at 2025 WCBP

    05 Sep 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-09-05/newron-to-present-data-and-updates-on-its-clinical-program-evaluating-evenamide-as-an-add-on-treatme

    PHARMAWEB
    05 Sep 2025
    Share Share
    Newron Preclinical Data: Evenamide May Ease Schizophrenia
    Newron Preclinical Data: Evenamide May Ease Schizophrenia

    11 Aug 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250811493586/en/Newron-Notes-the-Publication-of-New-Preclinical-Research-Suggesting-Evenamide-Ameliorates-Schizophrenia-Related-Dysfunction

    BUSINESSWIRE
    11 Aug 2025
    Share Share
    Newron Preclinical Data: Evenamide Aids Schizophrenia
    Newron Preclinical Data: Evenamide Aids Schizophrenia

    11 Aug 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-08-11/newron-notes-the-publication-of-new-preclinical-research-suggesting-evenamide-ameliorates-schizophre

    PHARMAWEB
    11 Aug 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.